Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.

When the first occurrence of major amputation and major adverse cardiovascular events are considered along with restenosis/reocclusion or TLR, the relative risk reduction increased to 20% in favor of edoxaban, but these differences did not reach statistical significance.

also in 111,027 other papers